Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Final Health Reform Bill Looks Positive For Pharma Firms

Executive Summary

It has been a long haul to get to the final iteration of proposed health care reform legislation released March 18, and it appears that the pharmaceutical industry's patience and lobbying efforts have garnered an overall positive result

You may also be interested in...

OIG's 2012 Agenda Includes Several New Part D, Part B Drug Issues

OIG's 2012 Agenda Includes Several New Part D, Part B Drug Issues

Coverage, Courts And Congress: News In Brief

Congress again seeks to restrict reverse settlements: Sen. Herb Kohl, D-Wis., proposed an amendment to a tax bill that would amend the Federal Trade Commission Act so that agreements between brand and generic companies to settle patent infringement claims are presumed to have anticompetitive effects if the ANDA filer receives anything of value and agrees to limit or forgo research, development or sales of its product. The presumption shall not apply if the parties "demonstrate by clear and convincing evidence that the precompetitive benefits of the agreement outweigh the anticompetitive effects of the agreement." Kohl introduced the amendment, SA 4332, on June 9 for inclusion in the American Jobs and Closing Tax Loopholes Act, H.R. 4213. Legislators had previously pushed for a similar amendment to render such deals illegal in the health care reform bill (1"The Pink Sheet," March 22, 2010)

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts